On April20, 2017,
the Court entered an order preliminarily approving the
Stipulation and the Settlement contemplated therein, and
providing for notice on this Form 8-K (the Preliminary Approval
Order). The Preliminary Approval Order further provides that the
Court will hold a hearing (Final Hearing) on June19, 2017 at
10:00 a.m. before the Honorable Terry J. Hatter, Jr. in Courtroom
9B of the United States District Court for the Central District
of California, First Street Federal Courthouse, 350 W. 1st
Street, 9th Floor, Los Angeles, CA 90012, to Federal Rule of
Civil Procedure 23.1, to among other things: (i)determine whether
the proposed Settlement is fair, reasonable and adequate and in
the best interests of the Company and its shareholders;
(ii)consider any objections to the Settlement submitted in
accordance with the Notice; (iii)determine whether a Final
Judgment substantially in the form attached as Exhibit C to the
Stipulation should be entered dismissing all claims in the Oglina
Action with prejudice and releasing the Released Claims against
the Released Persons; (iv)consider the payment to Plaintiffs
Counsel of attorneys fees and for the reimbursement of expenses;
(v)consider the payment to Plaintiffs and the Demand Shareholder
of Service Awards in an amount not to exceed $2,500 each, which
will be funded from the Fee and Expense Award; and (vi)consider
any other matters that may properly be brought before the Court
in connection with the Settlement.

Any Ampio
Shareholder who wishes to object to the fairness, reasonableness,
or adequacy of the Settlement as set forth in the attached
Stipulation, or to the proposed awards of attorneys fees and
expenses, may file an objection. An objector must file with the
Court a written statement of his, her or its objection(s): (a)
clearly indicating that objectors name, mailing address, daytime
telephone number, and e-mail address (if any); (b) stating that
the objector is objecting to the proposed Settlement or award of
attorneys fees and expenses in Oglina v. Macaluso, Case No.
2:15-cv-5970-TJH-PJW (C.D. Cal.); (c) specifying the reason(s),
if any, for each

such objection
made, including any legal support and/or evidence that such
objector wishes to bring to the Courts attention or introduce in
support of such objection; and (d)identifying and supplying
documentation showing how many shares of Ampio common stock the
objector owned as of April14, 2017, when the objector purchased
or otherwise acquired such shares, and proof that the objector
still owns such Ampio shares.

The objector must
file such objections and supporting documentation with the Clerk
of the Court, U.S. District Court Central District of California,
Western Division, First Street Federal Courthouse, 350 W. 1st
Street Los Angeles, CA 90012, not later than twenty-one (21)days
prior to the Final Hearing, and, by the same date, copies of all
such papers must also received by each of the following
persons:

Settlement
Counsel:

Timothy W. Brown,
Esq.

THE BROWN LAW
FIRM, P.C.

240 Townsend
Square

Oyster Bay, NY
11771

Counsel
for Defendants and Ampio:

Deborah S.
Birnbach, Esq.

GOODWIN PROCTER
LLP

100 Northern
Avenue

Boston, MA
02210

An objector may
file an objection on his, her or its own or through an attorney
hired at his, her or its own expense. If an objector hires an
attorney to represent him, her or it for the purposes of making
such objection to this paragraph, the attorney must effect
service of a notice of appearance on the counsel listed above and
file such notice with the Court no later than twenty-one (21)
days before the Final Hearing. Any Ampio Shareholder who does not
timely file and serve a written objection complying with the
terms of this paragraph shall be deemed to have waived, and shall
be foreclosed from raising, any objection to the Settlement, and
any untimely objection shall be barred. Any submissions by the
Parties in opposition or response to objections shall be filed
with the Court no later than seven (7)days before the Final
Hearing.

Any objector who
files and serves a timely, written objection in accordance with
the instructions above and herein, may appear at the Final
Hearing either in person or through counsel retained at the
objectors expense. Objectors need not attend the Final Hearing,
however, in order to have their objections considered by the
Court. Timely objectors or their attorneys intending to appear at
the Final Hearing are required to indicate in their written
objection (or in a separate writing submitted to the counsel
listed in the preceding paragraph no later than twenty-one
(21)days prior to the Final Hearing) that they intend to appear
at the Final Hearing and identify any witnesses they may call to
testify and exhibits they intend to introduce into evidence at
the Final Hearing. Objectors or their attorneys intending to
appear at the Final Hearing must also, no later than twenty-one
(21)days prior to the Final Hearing, file with the Court, and
serve upon counsel listed in the above paragraph, a notice of
intention to appear, setting forth the name and address of anyone
intending to appear. Any objector who does not timely file and
serve a notice of intention to appear in accordance with this
paragraph shall not be permitted to appear at the Final Hearing,
except for good cause shown.

If you are a
current holder of Ampio common stock and do not take steps to
appear in this action and object to the proposed Settlement, you
will be bound by the Final Judgment of the Court and will forever
be barred from raising an objection to such settlement in this or
any other action or proceeding, and from pursuing any of the
Released Claims.

If you held Ampio
common stock as of April14, 2017 and continue to hold such stock,
you may have certain rights in connection with the proposed
Settlement. You may obtain further information by contacting
Settlement Counsel at: Timothy W. Brown, Esq., The Brown Law
Firm, P.C., 240 Townsend Square, Oyster Bay, New York 11771,
Telephone: (516) 922-5427, [email protected].

Item9.01
Financial Statements and Exhibits.

About AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE)

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Recent Trading Information

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) closed its last trading session up +0.162 at 0.721 with 117,465 shares trading hands.